Conditions: Hepatitis C Virus (HCV)
Keywords: HCV Infection Chronic Hepatitis C Virus Hepatitis C Virus (HCV) Genotype 1b
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 650
Healthy volunteers: no

Brief summary:
This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.

Detailed description:

Arms:
arm 1: Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) for 12 weeks. arm 2: Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) for 12 weeks.

Interventions: intervention 1: ombitasvir/paritaprevir/ritonavir and dasabuvir intervention 2: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
Intervention descriptions: intervention 1: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet intervention 2: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

Protocol document: